NEW YORK (GenomeWeb News) - Compugen today posted $40,000 in revenues for the second quarter of 2008, compared to no revenues in the comparable period of 2007, accompanied by a 6 percent improvement in its second-quarter net loss.
 
The company also announced the appointment of Dikla Czaczkes Axselbard as chief financial officer, succeeding Ronit Lerner who resigned from the company. Axselbard served as director of finance for Compugen from 2002 through 2007, and has served as acting CFO since February.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.